Dementia, life expectancy and nursing home care
Researchers from a large meta-analysis of relevant studies have reported that the average life expectancy of people with dementia at time of diagnosis ranges from 5.7 years at… read more.
Researchers from a large meta-analysis of relevant studies have reported that the average life expectancy of people with dementia at time of diagnosis ranges from 5.7 years at… read more.
Researchers report that most treatments for pregnant women with MS (multiple sclerosis) do not lead to increased risks of major adverse outcomes. “We found that most therapies were… read more.
Atogepant, an oral drug approved to prevent migraine, appears to also alleviate migraine symptoms early after onset has begun. The findings were reported on December 23, 2024 in… read more.
Use of antibiotics by healthy elderly persons does not cause an increase in the risk of cognitive impairment or dementia, researchers reported on December 18, 2024 in Neurology…. read more.
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study funded by the National… read more.
In cognitive science, there has recently been increasing attention to the relationship between sports expertise and working memory. However, to date, no meta-analysis has compared the working memory… read more.
Eisai Co., Ltd and Biogen Inc. announced that the latest findings for lecanemab-irmb (U.S. brand name: Leqembi), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of early… read more.
Plus Therapeutics a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will have multiple opportunities to present data at the… read more.
Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks… read more.
UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild… read more.
The study, published in Lancet Neurology, detailed the “head-to-head” trial implemented by the researchers to test two drugs, mexiletine and lamotrigine, on people with the condition. The trial, which… read more.
A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.